$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

$uncy Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000121390022071557 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$951.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.485M	$163.0K	$939.0K
YoY Change	6.76%	-82.64%	192.52%
% of Gross Profit
Research & Development	$3.840M	$4.803M	$3.776M
YoY Change	182.15%	27.2%	1142.11%
% of Gross Profit
Depreciation & Amortization	$2.000K	$1.000K
YoY Change	100.0%
% of Gross Profit
Operating Expenses	$5.325M	$6.505M	$4.715M
YoY Change	93.5%	37.96%	654.4%
Operating Profit		-$5.554M	-$4.715M
YoY Change		17.79%
Interest Expense	-$3.000K	$3.000K	-$55.00K
YoY Change		-105.45%	-28.57%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$3.000K	-$431.0K
YoY Change		-99.3%
Pretax Income	-$5.328M	-$5.557M	-$5.201M
YoY Change	93.6%	6.84%	640.88%
Income Tax
% Of Pretax Income
Net Earnings	-$5.328M	-$5.557M	-$5.201M
YoY Change	93.6%	6.84%	640.88%
Net Earnings / Revenue		-584.33%
Basic Earnings Per Share		-$0.37	-$0.37
Diluted Earnings Per Share	-$0.35	-$0.37	-$367.1K
COMMON SHARES
Basic Shares Outstanding	15.09M shares	15.05M shares	14.17M shares
Diluted Shares Outstanding		15.06M shares	14.17M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$455.0K	$7.010M	$18.01M
YoY Change	-97.26%	-61.08%	28488.89%
Cash & Equivalents	$455.0K	$7.010M	$18.01M
Short-Term Investments
Other Short-Term Assets	$2.189M	$2.952M	$1.771M
YoY Change	19.49%	66.69%	1035.26%
Inventory	$2.189M	$2.952M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.644M	$9.962M	$19.78M
YoY Change	-85.64%	-49.64%	8932.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.00K	$24.00K
YoY Change	-21.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$174.0K	$215.0K	$0.00
YoY Change	-47.75%
TOTAL ASSETS
Total Short-Term Assets	$2.644M	$9.962M	$19.78M
Total Long-Term Assets	$174.0K	$215.0K	$0.00
Total Assets	$2.818M	$10.18M	$19.78M
YoY Change	-84.97%	-48.55%	8932.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$892.0K	$2.292M	$49.00K
YoY Change	20.22%	4577.55%	-77.31%
Accrued Expenses	$2.237M	$3.065M	$633.0K
YoY Change	84.57%	384.2%	681.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$103.0K
YoY Change		-100.0%	-87.11%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.284M	$5.522M	$785.0K
YoY Change	56.01%	603.44%	-62.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$29.00K
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$29.00K	$0.00
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.284M	$5.522M	$785.0K
Total Long-Term Liabilities	$0.00	$29.00K	$0.00
Total Liabilities	$3.284M	$5.551M	$785.0K
YoY Change	45.31%	607.13%	-62.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.00M	-$28.67M
YoY Change	113.29%
Common Stock	$15.00K	$15.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$466.0K	$4.626M	$19.00M
YoY Change
Total Liabilities & Shareholders Equity	$2.818M	$10.18M	$19.78M
YoY Change	-84.97%	-48.55%	8932.88%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$5.328M	-$5.557M	-$5.201M
YoY Change	93.6%	6.84%	640.88%
Depreciation, Depletion And Amortization	$2.000K	$1.000K
YoY Change	100.0%
Cash From Operating Activities	-$6.084M	-$3.563M	-$3.474M
YoY Change	333.64%	2.56%	392.07%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$22.27M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-471.0K	0.000	21.48M
YoY Change		-100.0%	2697.4%
NET CHANGE
Cash From Operating Activities	-6.084M	-3.563M	-3.474M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	-471.0K	0.000	21.48M
Net Change In Cash	-6.555M	-3.563M	18.01M
YoY Change	357.75%	-119.78%	28948.39%
FREE CASH FLOW
Cash From Operating Activities	-$6.084M	-$3.563M	-$3.474M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$6.084M	-$3.563M
YoY Change	342.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40582
	dei	Entity Registrant Name EntityRegistrantName	UNICYCIVE THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3638692
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4300 El Camino Real
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Altos
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94022
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	351-4495
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	UNCY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15088670	shares
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16579000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7010000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1832000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2952000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	18411000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	9962000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	305000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2021Q4	us-gaap	Assets Assets	18744000	usd
CY2022Q3	us-gaap	Assets Assets	10177000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	742000	usd
	us-gaap	Interest Expense InterestExpense	628000	usd
	us-gaap	Interest Expense InterestExpense	3000	usd
CY2021Q3	uncy	Loss On Debt Conversion LossOnDebtConversion	-431000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2292000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1212000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3065000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	151000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	165000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2105000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5522000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2260000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	5551000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14996534	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14996534	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15087943	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15087943	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	32408000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33280000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15939000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28669000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4626000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18744000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10177000	usd
CY2022Q3	us-gaap	Revenues Revenues	951000	usd
	us-gaap	Revenues Revenues	951000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3776000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4803000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4719000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8596000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	939000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1702000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1506000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5082000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	4715000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	6505000	usd
	us-gaap	Operating Expenses OperatingExpenses	6225000	usd
	us-gaap	Operating Expenses OperatingExpenses	13678000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4715000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5554000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6225000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12727000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	55000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	3000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-3402000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1100000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15050389	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2671000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-964000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	31000	usd
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	202000	usd
	uncy	Loss On Debt Conversion LossOnDebtConversion	-431000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-486000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1040000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5201000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5557000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7265000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12730000	usd
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14167098	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15061995	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10538473	shares
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	294000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-4202000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-5201000	usd
CY2021Q3	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2700000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22271000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3685000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2191000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	239000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	18997000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16484000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3537000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	290000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	13244000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3636000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	294000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9910000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-5557000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	266000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	4626000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7265000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12730000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2191000	usd
	us-gaap	Depreciation Depreciation	5000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	735000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	850000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	488000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	139000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	114000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	19000	usd
	uncy	Deferred Compensation To Ceo DeferredCompensationToCEO	249000	usd
	uncy	Loss On Debt Conversion LossOnDebtConversion	-431000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1709000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-397000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	58000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	463000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1908000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-111000	usd
	uncy	Related Party Service Fee Payable RelatedPartyServiceFeePayable	9000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4364000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9567000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	22271000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	248000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1098000	usd
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	1361000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	119000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22375000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18011000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9569000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16579000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18011000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7010000	usd
	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets	1517000	usd
	uncy	Licensing Revenue LicensingRevenue	1000000	usd
CY2021Q4	uncy	Accmulated Deficit AccmulatedDeficit	15900000	usd
CY2022Q3	uncy	Accmulated Deficit AccmulatedDeficit	28700000	usd
	uncy	Aggregate Amount AggregateAmount	1100000	usd
CY2022Q3	us-gaap	Cash Cash	7000000	usd
	uncy	Financial Term FinancialTerm	P1Y
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the periods presented. Management believes that these estimates and assumptions are reasonable; however, actual results may differ and could have a material effect on future results of operations and financial position. Significant items subject to such estimates and assumptions include progress estimates for material third party research and development contracts, stock-based compensation and fair value of the Company’s common stock prior to the Company’s IPO. Actual results may materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
CY2022Q3	uncy	Concentration Risk Percentage ConcentrationRiskPercentage	0.20	pure
	uncy	Concentration Risk Percentage ConcentrationRiskPercentage	0.20	pure
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	800000	usd
CY2022Q3	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	800000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. All of the Company’s cash was deposited in one account at a financial institution, and the account balance may at times exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institution in which the cash is held.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p>
	uncy	Income Tax Largest Amount IncomeTaxLargestAmount	0.50	pure
CY2022Q3	us-gaap	Discontinued Operation Amounts Of Material Contingent Liabilities Remaining DiscontinuedOperationAmountsOfMaterialContingentLiabilitiesRemaining	100000	usd
CY2022Q3	us-gaap	Defined Benefit Plan Funded Percentage DefinedBenefitPlanFundedPercentage	0.10	pure
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	222000	usd
CY2021Q4	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	885000	usd
CY2022Q3	uncy	Prepaid Preclinical Services PrepaidPreclinicalServices	2661000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	126000	usd
	uncy	Significant Agreements Policies SignificantAgreementsPolicies	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Significant Agreements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regards to manufacturing, testing and potential commercial supply of Renazorb, the Company has entered into an agreement with Shilpa Medicare Ltd based in India. According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor. Unicycive is not obligated to make any payments to the vendor until FDA approval of the product is obtained and commercial revenue is generated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2017, the Company entered into an exclusive license agreement with Sphaera, a stockholder, for the rights to further develop the drug candidate, UNI 494, for commercialization. No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2018, the Company entered into an Assignment and Asset Purchase Agreement with Spectrum Pharmaceuticals, Inc. (“Spectrum Agreement”) pursuant to which the Company purchased certain assets from Spectrum, including Spectrum’s right, title, interest in and intellectual property related to Renazorb RZB 012, also known as RENALAN™ (“Renalan”) and RZB 014, also known as SPI 014 (“SPI” and together with Renalan, the “Compounds”), to further develop and commercialize Renazorb and related compounds. In partial consideration for the Spectrum Agreement, the Company issued 313,663 shares of common stock to Spectrum valued at approximately $4,000 which represented four percent of the Company on a fully-diluted basis at the date of the execution of the Spectrum Agreement. The Spectrum Agreement has an anti-dilution provision, which provides that Spectrum maintain its ownership interest in the Company at 4% of the Company’s shares on a fully-diluted basis. Fully-diluted shares of common stock for purposes of the Renazorb Purchase Agreement assumes conversion of any security convertible into or exchangeable or exercisable for common stock or any combination thereof, including any common stock reserved for issuance under a stock option plan, restricted stock plan, or other equity incentive plan approved by the Board of Directors of the Company immediately following the issuance of additional shares of the Company’s common stock (but prior to the issuance of any additional shares of common stock to Spectrum). Spectrum’s ownership shall not be subject to dilution until the earlier of thirty-six months from the first date the Company’s stock trades on a public market, or the date upon which the Company attains a public market capitalization of at least $50 million. On July 13, 2021, the Company’s initial public offering resulted in a public market capitalization of at least $50 million, and as a result the Company was required to issue 438,374 anti-dilution shares of common stock. This issuance represented the final anti-dilution calculation required under the Spectrum Agreement, and no further anti-dilution shares will be issued. The Company calculated the fair value of the shares and recognized $2.2 million to research and development expenses as cost to issue those shares during the third quarter of 2021. The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20<sup>th</sup>) anniversary of the Closing Date of the Renazorb Purchase Agreement. In August 2022, the Company received an upfront payment of approximately $1.0 million as a result of a sublicense development agreement with Lee’s Pharmaceutical (HK) Limited. The payment represents sublicense income as described in the Spectrum Agreement, and 20% of the amount received has been accrued as an R&D expense in the accompanying statements of operations for the three and nine months ended September 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, the Company entered into an agreement with Syneos Health LLC (“Syneos”) pursuant to which Syneos will provide preclinical research and analysis services related to the development of UNI-494. The budget for the services, which also includes clinical pharmacology, translational sciences, and bioanalytical services, is approximately $2.3 million. Related payments totaling approximately $1.2 million have been paid to Syneos as of September 30, 2022, approximately $2.0 million of related expense has been recorded, and approximately $0.8 million has been recorded as accounts payable or accrued expense in the accompanying balance sheet as of September 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited (“Quotient”), a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494. The budget for the study is approximately $3.7 million. Related payments totaling approximately $1.3 million have been paid to Quotient as of September 30, 2022, approximately $0.5 million of related expense has been recorded, and approximately $0.8 million has been recorded as prepaid expense in the accompanying balance sheet as of September 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc. (“CBCC”), a California based company that provides clinical trial and related services, for the purpose of performing clinical research in support of Renazorb. The budget for the initial study was approximately $1.4 million. Payments relating to the initial agreement totaling approximately $0.3 million have been paid to CBCC as of September 30, 2022, and approximately $0.4 million of related expense has been recorded. In September 2022, a statement of work revised the remaining services budget to approximately $0.1 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 29, 2022, the Company entered into an Agreement with Inotiv, an Indiana based company that provides preclinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $1.0 million. Approximately $0.3 million has been paid to Inotiv as of September 30, 2022 and approximately $0.2 million has been recorded as prepaid expense in the accompanying balance sheet as of September 30, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 14, 2022, the Company entered into a license agreement with Lee’s Pharmaceutical (HK) Limited (see Note 4). Under the terms of the agreement, Lee’s Pharmaceutical will be responsible for development, registration filing and approval for Renazorb in China, Hong Kong, and certain other Asian markets. In addition, Lee’s Pharmaceutical will have sole responsibility for the importation of the drug product from the Company and for the costs of commercialization of Renazorb in the licensed territories. The Company has received an upfront payment of $1.0 million, expects to receive up to $1.0 million in milestone payments upon product launch in China and will be eligible for tiered royalties of between 7% and 10% upon achievement of prespecified regulatory and commercial achievements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022, the Company entered into an Agreement with Celerion, a Nebraska based company that provides clinical trial and related services, for the purpose of performing research in support of Renazorb. The budget for the services is approximately $2.7 million. Approximately $0.8 million has been paid to Celerion as of September 30, 2022. $1.4 million has been recorded as prepaid expense with $0.6 million recorded in accounts payable based on contractual terms for future clinical services as of September 30, 2022.</p>
	us-gaap	Debt Instrument Description DebtInstrumentDescription	According to the terms of the agreement Unicycive will pay the vendor $2 million in the first calendar year when the net revenue reaches $10 million from sales of Renazorb following its approval by the FDA and commercial supply of the product by the vendor (First Payment). Thereafter, the Company will pay $2 million per year for four consecutive years, after the first year’s payment, for the total payments of $10 million, provided all commercial supplies are continued to be manufactured and supplied by the vendor.
CY2017Q4	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	No payments were made upon execution of the agreement but rather payments for $50,000 will be due commencing with the initiation by the Company of a second clinical trial and $50,000 on completion of such trial. At the time the FDA accepts a NDA application submitted by the Company for the product, the Company will pay Sphaera $1.65 million. Upon commercialization and sale of the drug product, royalty payments will also be payable quarterly to Sphaera equal to 2% of net sales on the preceding quarter.
CY2021Q3	us-gaap	Capitalization Longterm Debt And Equity CapitalizationLongtermDebtAndEquity	50000000	usd
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Equity Forward Agreements IncrementalCommonSharesAttributableToEquityForwardAgreements	438374	shares
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2200000	usd
	uncy	Purchase Agreement Description PurchaseAgreementDescription	The Company is also required to pay Spectrum 40% of all of the Company’s sublicense income for any sublicense granted to certain sublicensees during the first 12 months after the Closing Date (as that term is defined in the Renazorb Purchase Agreement) and 20% of all other sublicense income. The Company’s payment obligations to Spectrum will expire on the twentieth (20th) anniversary of the Closing Date of the Renazorb Purchase Agreement.
CY2022Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1000000	usd
CY2022Q3	uncy	Royalties Percentage RoyaltiesPercentage	0.07	pure
CY2022Q3	uncy	Regulatory And Commercial Achievements Percentage RegulatoryAndCommercialAchievementsPercentage	0.10	pure
	us-gaap-sup	Debt And Equity Securities And Foreign Currency Transaction Price Change Unrealized Gain Loss Operating Before Tax DebtAndEquitySecuritiesAndForeignCurrencyTransactionPriceChangeUnrealizedGainLossOperatingBeforeTax	1000000	usd
CY2022Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1000000	usd
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1000000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	821000	usd
CY2022Q3	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	69000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1832000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	2952000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	15000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	14000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	15000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	713000	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2216000	usd
CY2021Q4	uncy	Credit Card Liability CreditCardLiability	29000	usd
CY2022Q3	uncy	Credit Card Liability CreditCardLiability	76000	usd
CY2021Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	742000	usd
CY2022Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2292000	usd
CY2021Q4	uncy	Accrued Labor Costs AccruedLaborCosts	691000	usd
CY2022Q3	uncy	Accrued Labor Costs AccruedLaborCosts	1823000	usd
CY2021Q4	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	369000	usd
CY2022Q3	uncy	Accrued Drug Development Costs AccruedDrugDevelopmentCosts	1115000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	152000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	127000	usd
CY2021Q4	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	1212000	usd
CY2022Q3	us-gaap	Accrued Reclamation Costs Current AccruedReclamationCostsCurrent	3065000	usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	736773	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y6M14D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6
CY2021Q3	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	191000	usd
CY2021Q3	uncy	Conversion Shares Issued Percentage ConversionSharesIssuedPercentage	0.25	pure
	uncy	Received Advances From The Stockholder ReceivedAdvancesFromTheStockholder	248000	usd
	uncy	Repaid Amounts Owed To The Stockholder RepaidAmountsOwedToTheStockholder	1361000	usd
CY2017Q3	us-gaap	Shares Issued SharesIssued	62181	shares
CY2017Q3	us-gaap	Share Price SharePrice	0.013
	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	6000	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Share Price SharePrice	5
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	184193	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	4784193	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y9M14D
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each holder of shares of common stock shall be entitled to one vote for each share thereof held.
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1302326	shares
CY2020Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	348837	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	1767442	shares
CY2020	us-gaap	Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance	465116	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	17442	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1211068	shares
CY2021Q4	uncy	Weighted Average Exercise Price Options Outstanding Beginning WeightedAverageExercisePriceOptionsOutstandingBeginning	3.19
CY2022Q3	uncy	Weighted Average Remaining Contractual Term Outstanding WeightedAverageRemainingContractualTermOutstanding	P8Y7M28D
CY2021Q4	uncy	Aggregate Intrinsic Value Outstanding Beginningin Dollars AggregateIntrinsicValueOutstandingBeginninginDollars	321000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	19000	shares
	uncy	Number Of Shares Underlying Outstanding Options Options Exercised NumberOfSharesUnderlyingOutstandingOptionsOptionsExercised	64671	shares
	uncy	Weighted Average Exercise Price Options Exercised WeightedAverageExercisePriceOptionsExercised	0.34
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1165397	shares
CY2022Q3	uncy	Weighted Average Exercises Price Outstanding Ending WeightedAverageExercisesPriceOutstandingEnding	3.31
	uncy	Sharebased Compensation Arrangement By Sharebased Payments Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentsAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P8Y3M10D
CY2022Q3	uncy	Aggregate Intrinsic Value Outstanding Ending AggregateIntrinsicValueOutstandingEnding	57000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	640747	shares
	uncy	Weighted Exercise Price Option Vested And Exercisable WeightedExercisePriceOptionVestedAndExercisable	3.23
	uncy	Share Based Weighted Average Remaining Contractual Term Shares Vested And Exercisable Share-basedWeightedAverageRemainingContractualTermSharesVestedAndExercisable	P7Y11M19D
	uncy	Aggregate Intrinsic Value Options Vested And Exercisable AggregateIntrinsicValueOptionsVestedAndExercisable	57000	usd
	uncy	Grant Date Fair Value Of Options GrantDateFairValueOfOptions	11000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Number Of Shares Period Increase Decrease SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfSharesPeriodIncreaseDecrease	1300000	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2021Q1	uncy	Description Of Consulting Exercised DescriptionOfConsultingExercised	During the three months ended March 31, 2021, employees and consultants exercised a total of 383,721 stock options and the Company received $119,000 in proceeds. A portion of these options were exercised early (prior to vesting), and as of September 30, 2022, 11,726 of the options remained unvested. Proceeds received related to the unvested options of approximately $38,000 at September 30, 2022 were recorded in accrued liabilities on the accompanying balance sheets and will be reclassified to equity as vesting occurs, provided the employees and consultants continue to provide services to the Company. Proceeds received related to the vested portion of options of $51,000 and $22,000 were reclassified to equity during the nine-month periods ended September 30, 2021 and 2022, respectively. The vested portion of the exercises was 371,988 shares at September 30, 2022.
	uncy	Loss On Debt Conversion LossOnDebtConversion		usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2021Q3	uncy	Research And Development ResearchAndDevelopment	167000	usd
CY2022Q3	uncy	Research And Development ResearchAndDevelopment	103000	usd
	uncy	Research And Development ResearchAndDevelopment	623000	usd
	uncy	Research And Development ResearchAndDevelopment	303000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	72000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	163000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	547000	usd
CY2021Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	239000	usd
CY2022Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	266000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	735000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	850000	usd
	uncy	Expected Dividend ExpectedDividend	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5949590	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5201000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5557000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7265000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12730000	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14167098	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15061995	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10538473	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15050389	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2021Q3	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	822457	shares
CY2022Q3	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1165397	shares
	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	822457	shares
	uncy	Options To Purchase Common Stock OptionsToPurchaseCommonStock	1165397	shares
CY2021Q3	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2022Q3	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
	uncy	Warrants To Purchase Common Stock WarrantsToPurchaseCommonStock	4784193	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5606650	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5949590	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5606650	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14167098	shares
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	uncy	Deferred Compensation To Ceo DeferredCompensationToCEO		usd
	uncy	Related Party Service Fee Payable RelatedPartyServiceFeePayable		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	uncy	Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets DeferredPreclinicalChargesIncludedInPrepaidExpensesAndOtherCurrentAssets		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15061995	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001766140

Files In Submission

Name	View Source	Status
0001213900-22-071557-index-headers.html	Edgar Link	pending
0001213900-22-071557-index.html	Edgar Link	pending
0001213900-22-071557.txt	Edgar Link	pending
0001213900-22-071557-xbrl.zip	Edgar Link	pending
f10q0922ex31-1_unicycive.htm	Edgar Link	pending
f10q0922ex31-2_unicycive.htm	Edgar Link	pending
f10q0922ex32-1_unicycive.htm	Edgar Link	pending
f10q0922ex32-2_unicycive.htm	Edgar Link	pending
f10q0922_unicycivethera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
f10q0922_unicycivethera_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
uncy-20220930.xsd	Edgar Link	pending
uncy-20220930_cal.xml	Edgar Link	unprocessable
uncy-20220930_def.xml	Edgar Link	unprocessable
uncy-20220930_lab.xml	Edgar Link	unprocessable
uncy-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy

2022 Q4 Form 10-Q Financial Statement

#000121390022071557 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY Unicycive Therapeutics, Inc. Stock $uncy

2022 Q4 Form 10-Q Financial Statement

#000121390022071557 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UNCY
Unicycive Therapeutics, Inc. Stock $uncy